ALDX Aldeyra Therapeutics Inc

$ALDX could be totally wrong but a webcast seems more bullish than a PR stating the meeting did not go well with FDA. Who knows

$ALDX Todd would never show his face if news was bad we all know that… I expect him to announce the next phase aka formal dispute filed for panel review like $OTLK

$ALDX feeling bad for those who held. There is no hope on this company... the CRL was very clear no matter the sugar coating by the company and CEO. I lost alot on this myelf :(

$ALDX their lawyers and the board chose to pursue a strategy which they know is flawed. i’ll put out a more comprehensive tweet. this appeal doesnt have any chance of achieving anything

$ALDX IMO will need a miracle for their eye drug to get approved. Glad I sold this piece of shit and basically broke even. Todd is was what I would say “getting high on your own supply”.

$ALDX volume is much lighter today after that 4 million block yesterday. let me see over $1 tomorrow.

$ALDX I hope Todd was on the debate team in college. It’s going to take a performance of a life time to convince the FDA. I got 43k shares ridding on this guy. SMH!

$ALDX Is it really any wonder? Todd has been lying to us for years. Nothing he said was true.

$ALDX noted it will appeal the FDA's CRL for reproxalap and seek a dispute resolution, extending cash runway to 2029.

$ALDX I wonder how on tomorrow will go?🫣 I honestly don’t trust ALDX, but I have too much money into it to leave.

$ALDX Legal Update FYI: Case #1:26-cv-11510 Docket #34 Massachusetts Federal District Court, Judge Denise Casper Kirby v. Aldeyra Therapeutics, Inc. CLASS ACTION Amended complaint submitted on schedule Oct 9th and is available as pdf for download through PACER federal website for purchase ($3.00). Requested ChatGPT-5 do a legal analysis of the original complaint filed Mar 16, 2026 comparing it to the finalized amended complaint, now 48 pages in length. AI analysis shows the amended complaint is vastly more sophisticated than the early initial allegations and ChatGPT-5 gives it 65-70% favorable odds of surviving/partially surviving a defendant motion for dismissal. Stay tuned...

$ALDX $130K at $6? Sold at $5.88. Count my blessings everyday. Down 100k twice.. would’ve been third time, but idk just sold it due to family issues..I can’t imagine having a $13K position..

$ALDX Headed for $1.00 land imo... We got 2 overnight winners already need this one to go... Bounce time.. Ignore the posts that's have nothing to do with this stock.... This is a shame👇👇

$ALDX FDA is saying something like, this may work but it’s unclear for the group or use you want to claim. Tell us why failed studies failed so we can see if there’s an explanation. Tell us if there’s a group where is does clearly work. I’m long and I have to say, I understand the concerns. I think OND sides with past decision. The question would be, then, what now?

$ALDX Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease https://www.businesswire.com/news/home/20260929404066/en/Aldeyra-Therapeutics-Announces-Intent-to-Submit-Formal-Dispute-Resolution-Request-for-Reproxalap-to-Treat-Dry-Eye-Disease • Submission of the FDRR and a meeting with the OND are expected in the fourth quarter of 2026. ♦ The decision to submit the FDRR is based on the outcome of recent Type A and Type D meetings with the FDA. • Conference call this morning at 8:00am ET to discuss the FDRR.

$ALDX Aldeyra Therapeutics to Host Regulatory Update Webcast https://www.businesswire.com/news/home/20260928058014/en/Aldeyra-Therapeutics-to-Host-Regulatory-Update-Webcast ALDX will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00am ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.

$ALDX What sh*t stock , $0.50 by the end of the month . Might take another gamble and buy more to bring down my $1.53 holding price

$ALDX what a dog turd this stock and company has become. All they’ve done is burn cash and make zero progress on actually selling any product. Absolute shit show…

$ALDX My prediction is that this company will not remain standalone. When you look at the pipeline, it is too long and too perilous to bring other molecules to market. If the board is doing its job, they must see that. The question will be timing and price. My over/under is 12 months. Price will depend on the outcome of the review (e.g., whether another acute trial is necessary) and the strategy selected.

$ALDX this was just 1.44 few days ago.. this should move up into FDA catalyst. Funds into 2029.